The onus is firmly upon medtech players to become much more “patient-centric” in both their operations and the end solutions that they provide
In Conversation
Previously, many organizations seeking a European presence would begin by setting themselves up in the UK, but now, they must look for other locations on the…
When I decided to re-join Big Pharma, I was keen to reevaluate how the interactions between the industry and healthcare players have developed in the face…
In order to be successful in neuroscience, we have to be focused and entirely dedicated as experts.
Above all, Aspen is much more than a regular pharma company
My mission is very clearly to raise the profile of the French affiliate within the UCB Group and simultaneously to increase the company’s footprint within France’s…
Our neighbours envy the Temporary Authorization of Use (Autorisation Temporaire d’Utilisation / ATU) system that we have in France, and I think they have good reason…
We started with contraception and after a few years became the market leader in France, ahead of big pharma players like Pfizer, Bayer, and MSD
While the continuation of outsourcing by pharmaceutical companies is a trend, I am paying more attention to how the final product market is evolving
Even though our social security system is now 70 years old, it has evolved over time and was able to adapt to the changing needs of…
Overall, we are a very important branch of the Merck group and we have a positive impact on the French economy, with significant investments in this country
Lyon carries a number of strategic advantages: economically speaking, office spaces are significantly cheaper than in Paris, and Lyon offers a high quality of life with…
